The tumor microenvironment in renal cell cancer

Por Mier, James W.
Publicado no Curr Opin Oncol (2019)

CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors

Por Saxena, Ruchi, Wang, Yan, Mier, James W.
Publicado no Melanoma Res (2020)

Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma

Por Liu, Qingjun, Mier, James W, Panka, David J
Publicado em 2011

An inexpensive, specific and highly sensitive protocol to detect the Braf(V600E) mutation in melanoma tumor biopsies and blood

Por Panka, David J, Sullivan, Ryan J, Mier, James W
Publicado em 2010

Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

Por Thummalapalli, Rohit, Melms, Johannes C., Mier, James, Izar, Benjamin
Publicado no Melanoma Res (2020)

Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b(+)/Gr-1(+) myeloid derived suppressor cells

Por Panka, David J, Liu, Qingjun, Geissler, Andrew K, Mier, James W
Publicado em 2013

Overexpression of Kinase Suppressor of Ras Upregulates the High-Molecular-Weight Tropomyosin Isoforms in ras-Transformed NIH 3T3 Fibroblasts

Por Janssen, Richard A. J., Kim, Phillia N., Mier, James W., Morrison, Deborah K.
Publicado em 2003

PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells

Por Zhu, Shudong, Cohen, Matthew B, Bjorge, Jeffrey D, Mier, James W, Cho, Daniel C
Publicado em 2013

Novel drugs that target the metabolic reprogramming in renal cell cancer

Por van der Mijn, Johannes C., Panka, David J., Geissler, Andrew K., Verheul, Henk. M., Mier, James W.
Publicado no Cancer Metab (2016)

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared to Rapamycin in Renal Cell Carcinoma

Por Cho, Daniel C., Cohen, Matthew B., Panka, David J., Collins, Michael, Ghebremichael, Musie, Atkins, Michael B., Signoretti, Sabina, Mier, James W.
Publicado em 2010

Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report

Por Melms, Johannes C., Ho, Ka-Wai, Thummalapalli, Rohit, Tyler, Janice, Brinker, Titus Josef, Singh, Veena, Sengupta, Soma, Mier, James, Izar, Benjamin
Publicado no Mol Clin Oncol (2018)

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling

Por Bhatt, Rupal S., Wang, Xiaoen, Zhang, Liang, Collins, Michael P., Signoretti, Sabina, Alsop, David C., Goldberg, S. Nahum, Atkins, Michael B., Mier, James W.
Publicado em 2010

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma

Por Wang, Xiaoen, Zhang, Liang, Goldberg, S Nahum, Bhasin, Manoj, Brown, Victoria, Alsop, David C, Signoretti, Sabina, Mier, James W, Atkins, Michael B, Bhatt, Rupal S
Publicado em 2011

Calpain Regulates Actin Remodeling during Cell Spreading

Por Potter, David A., Tirnauer, Jennifer S., Janssen, Richard, Croall, Dorothy E., Hughes, Christina N., Fiacco, Kerry A., Mier, James W., Maki, Masatoshi, Herman, Ira M.
Publicado em 1998

The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma()

Por Wang, Xiaoen, Bullock, Andrea J., Zhang, Liang, Wei, Lin, Yu, Dongyin, Mahagaokar, Kedar, Alsop, David C., Mier, James W., Atkins, Michael B., Coxon, Angela, Oliner, Jon, Bhatt, Rupal S.
Publicado em 2014

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Por Sullivan, Ryan J., Ibrahim, Nageatte, Lawrence, Donald P., Aldridge, Julie, Giobbie-Hurder, Anita, Hodi, F. Stephen, Flaherty, Keith T., Conley, Christine, Mier, James W., Atkins, Michael B., McDermott, David F.
Publicado no Oncologist (2015)

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression

Por Zhang, Liang, Bhasin, Manoj, Schor-Bardach, Rachel, Wang, Xiaoen, Collins, Michael P., Panka, David, Putheti, Prabhakar, Signoretti, Sabina, Alsop, David C., Libermann, Towia, Atkins, Michael B., Mier, James W., Goldberg, S. Nahum, Bhatt, Rupal S.
Publicado em 2011

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma

Por Wang, Xiaoen, Solban, Nicolas, Khanna, Prateek, Callea, Marcella, Song, Jiaxi, Alsop, David C., Pearsall, R. Scott, Atkins, Michael B., Mier, James W., Signoretti, Sabina, Alimzhanov, Marat, Kumar, Ravi, Bhasin, Manoj K., Bhatt, Rupal S.
Publicado no Oncotarget (2016)

Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer

Por Zhang, Liang, Wang, Xiaoen, Bullock, Andrea J., Callea, Marcella, Shah, Harleen, Song, Jiaxi, Moreno, Kelli, Visentin, Barbara, Deutschman, Douglas, Alsop, David C., Atkins, Michael B., Mier, James W., Signoretti, Sabina, Bhasin, Manoj, Sabbadini, Roger A., Bhatt, Rupal S.
Publicado no Clin Cancer Res (2015)

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

Por Sarantopoulos, John, Mita, Alain C., He, Aiwu, Wade, James L., Hsueh, Chung-Tsen, Morris, John C., Lockhart, A. Craig, Quinn, David I., Hwang, Jimmy, Mier, James, Zhang, Wenping, Wack, Claudine, Yin, Jian, Clot, Pierre-François, Rixe, Olivier
Publicado no Cancer Chemother Pharmacol (2017)